How to access Voxzogo from India — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Indian family of a child with achondroplasia — the most common form of disproportionate short stature — may receive a prescription for Voxzogo (vosoritide) from their treating paediatric endocrinologist or clinical geneticist. Voxzogo is FDA-approved to increase linear growth in paediatric patients with achondroplasia, developed by BioMarin Pharmaceutical. Achondroplasia is caused by a pathogenic variant in the FGFR3 gene; Voxzogo targets the downstream growth-plate pathway. In India, Voxzogo is not locally registered, which is why your paediatric endocrinologist will navigate the named-patient import pathway on your behalf.

This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Voxzogo is a C-type natriuretic peptide analogue administered as a once-daily subcutaneous injection, dosed by weight. Eligibility is based on genetic confirmation of achondroplasia (pathogenic FGFR3 variant) and open growth plates — treatment is intended for paediatric patients still growing. Your paediatric endocrinologist will confirm diagnosis, document baseline height and growth velocity, review bone age to confirm open epiphyses, and set up periodic monitoring. Families are trained in subcutaneous injection technique, site rotation, and on-treatment surveillance of blood pressure.

Is Voxzogo legally importable into India?

Yes — through the CDSCO / Drugs Controller General of India (DCGI) personal-use and hospital-sponsored named-patient import frameworks. India has a well-established personal-use import mechanism that is regularly used for rare-paediatric-disease therapies with no locally registered alternative. The route permits a registered medical practitioner — or, for personal use, the patient's legal guardian with physician documentation — to request import of a medicine approved by a recognised reference authority (FDA qualifies) where no clinically equivalent registered alternative exists.

For Indian families with relatives supporting care from abroad, the route is well-trodden, particularly at paediatric tertiary centres in Mumbai, Delhi, Chennai, Bangalore, and Hyderabad.

How the pathway works, step by step

1. Consultation with your treating paediatric endocrinologist or clinical geneticist. Genetic confirmation of achondroplasia and documentation of growth-plate status, baseline growth metrics, and the clinical rationale for Voxzogo.
2. Baseline assessment. Height, weight, growth velocity, bone age, and blood pressure baselines are recorded.
3. CDSCO personal-use / named-patient application. The physician or family files the application with clinical rationale, genetic report, patient identification, and product details.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Voxzogo from authorised distribution.
5. Cold-chain shipment. Voxzogo requires cold-chain handling; the product ships with continuous temperature monitoring and chain-of-custody documentation.
6. Arrival, training, and home administration. The hospital pharmacy releases the product to the family after injection-technique training, with monthly refills coordinated thereafter.

What documentation your physician needs

Your physician will typically need to provide:

• A clinical rationale letter confirming achondroplasia diagnosis, FGFR3 report, open-growth-plate status, and Voxzogo as the indicated treatment
• Verification of their Indian medical registration (MCI / NMC)
• A copy of the FGFR3 genetic diagnostic report
• Patient identifier and family address for the import record
• Planned dosing schedule based on weight, with a plan for weight-based adjustments as the child grows

Reserve Meds provides a physician documentation kit that bundles the templates CDSCO reviewers and Indian customs expect to see for rare-paediatric-disease named-patient imports.

Costs and timing

Voxzogo's US cash-pay reference cost is weight-dependent. Indicative 2026 annual cost for a paediatric patient sits in a broad range of roughly USD 320,000–400,000, with adolescents at the higher end. Treatment typically continues until growth-plate closure. International cold-chain logistics, customs clearance, CDSCO documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.

Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted and customs processing begins. Refills ship on a rolling basis against your monthly schedule.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: Indian families often coordinate paediatric rare-disease care across extended-family networks spanning continents. Our concierge case lead is structured to include whichever family members the parents designate — a grandparent in Pune, an aunt in the US, an uncle in the Gulf — on refill coordination and care-planning calls.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Voxzogo specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and for CDSCO / customs review.
• Logistics. Cold-chain, temperature-monitored shipment with customs clearance support.
• Concierge case lead. A named point of contact for the family, coordinating long-term refills and weight-based dose adjustments as the child grows.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating paediatric endocrinologist. We operate on a waitlist basis during our pre-launch phase.

Frequently asked

Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with appropriate documentation. Cross-border import for rare-paediatric-disease therapies with no local alternative is a well-established mechanism. See our trust and compliance page.

How long will treatment continue? Voxzogo is continued while growth plates remain open. Bone age assessment by your endocrinologist determines when therapy is no longer indicated.

What about the injection training? Your endocrinology team provides injection training. We support refill coordination and supply storage guidance for families.

Can the family abroad pay directly? Yes. Cross-border payment is common for rare-disease care supported by diaspora family, and we issue invoicing that family members in the US, UK, UAE, Canada, and Australia can settle directly.

Will insurance cover this? Cash-pay is the default. Some Indian private insurers and diaspora policies consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Voxzogo coordination in India.

Add me to the Voxzogo waitlist

---

Composite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.